If a supplied lot fails agreed specifications, we’ll replace it at no cost or refund its purchase price in full.
Quality test failed? Free replacement or full refund.
Off-spec? Free replacement or full refund.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epithalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
GIP/GLP incretin co-formulation · metabolic research blend
Overview
PeptideXpo's Retatrutide + Tirzepatide blend is a single-vial research co-formulation holding 20 mg of retatrutide alongside 40 mg of tirzepatide. Retatrutide (LY3437943) is a triple incretin agonist that engages the GLP-1, GIP, and glucagon receptors; tirzepatide (LY3298176) is a dual GIP/GLP-1 agonist. Each is an incretin-mimetic peptide backed by its own substantial clinical dataset — but the fixed-ratio pairing is a formulation convenience for research only, has never been evaluated as a combination product in a dedicated clinical trial, and should not be assumed to have any pharmacology beyond the additive behavior of its two well-characterized components. PeptideXpo supplies the blend as a lyophilized powder with per-component analytical documentation: the batch COA reports each peptide's MS identity and RP-HPLC purity rather than a single combined purity figure — the correct way to release a two-active blend; the measured fill ratio is available on request and listed on the COA when tested. Buyers who need to vary the ratio, or who want the two peptides as separate vials, should order the single-component SKUs instead. Supplied for research use only, not for human or veterinary use.
Who buys this, and why
Custom-blend buyers are almost always OEM clients building a branded product around a specific ratio of two or more peptides. The development workflow is collaborative: ratio target, analytical method to verify it, stability protocol in the chosen carrier, and packaging selection are all defined in the OEM brief before the first commercial run. Sample-stage volumes are usually 5-10 g of finished blend; commercial MOQ depends on the components.
Primary buyer fit: academic and contract research laboratories.
Specifications
Documentation available on request
Each picture is a low-resolution preview of a report's first page, with batch and report numbers covered. For the full, clear report, ask our sales team, naming the product and strength.
Batch COARetatrutide 20mg+Tirzepatide 40mg 20 mg + 40 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Independent test fails? Full refund. How it works
Regulatory note
Research-use-only reference material; not for human or veterinary use. The fixed combination is not a clinically validated product.
Frequently asked questions
No. Retatrutide and tirzepatide each have their own independent clinical development programs and datasets, but the fixed-ratio combination of the two has not been evaluated in a dedicated clinical trial. This blend is a research formulation only; any expectation of its behavior should be limited to the additive pharmacology of the two individually characterized components, and it should not be treated as a validated combination product.
A blend containing two distinct actives is released against per-component analytics, not a single combined number. PeptideXpo's batch COA for this SKU reports the MS identity and RP-HPLC purity of each peptide separately; the measured fill ratio (nominal 20 mg retatrutide + 40 mg tirzepatide) is available on request and listed on the COA when tested. A single 'blend purity' figure would be meaningless for a two-component product, so the per-component breakdown is the meaningful release record.
Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.
Related peptides